Impact of busulfan versus treosulfan dose intensity in myelofibrosis undergoing hematopoietic cell transplantation.
Journal
American journal of hematology
ISSN: 1096-8652
Titre abrégé: Am J Hematol
Pays: United States
ID NLM: 7610369
Informations de publication
Date de publication:
14 May 2024
14 May 2024
Historique:
revised:
28
04
2024
received:
19
03
2024
accepted:
03
05
2024
medline:
15
5
2024
pubmed:
15
5
2024
entrez:
14
5
2024
Statut:
aheadofprint
Résumé
One key aspect of allogeneic hematopoietic cell transplantation (HCT) is pretransplant conditioning, balancing risk for relapse versus non-relapse mortality. Conditioning regimens with different alkylators at different doses can influence outcome, but data are missing for myelofibrosis, a challenging cohort of patients usually presenting at older age and with comorbidities. We evaluated in a multicenter retrospective study the comparative efficacy and safety of busulfan versus treosulfan in combination with fludarabine for myelofibrosis patients undergoing HCT. This study included 1115 patients (busulfan, n = 902; treosulfan, n = 213) receiving first HCT between 2005 and 2021. Patients were generally balanced for key patient characteristics. Overall survival at 4 years was 62% for the busulfan group versus 58% for the treosulfan group (p = .22). Impact on outcome was dose-dependent. Overall survival was 65% (95% CI, 61%-69%) for reduced intensity busulfan versus 69% (95% CI, 54%-84%) for reduced intensity treosulfan, 53% (95% CI, 44%-63%) for higher intensity busulfan, and 55% (95% CI, 46%-63%) for higher intensity treosulfan. Incidence of relapse was similar across intensity groups. In multivariable analysis, the hazard for death (with reduced intensity busulfan as reference) was 0.88 (95% CI, 0.39-2.01) for reduced intensity treosulfan (p = .77), 1.42 (95% CI, 0.96-2.10) for higher intensity busulfan (0.08), and 1.61 (95% CI, 1.14-2.26) for higher intensity treosulfan (p = .006). In terms of non-relapse mortality, comparison was not significantly different, while the hazard ratio for higher intensity treosulfan was 1.48 (95% CI, 0.98-2.23; p = .06). Here, we showed comparable outcomes and improved survival in myelofibrosis undergoing HCT with reduced intensity busulfan or treosulfan.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024 The Authors. American Journal of Hematology published by Wiley Periodicals LLC.
Références
Kroger N, Bacigalupo A, Barbui T, et al. Indication and management of allogeneic haematopoietic stem‐cell transplantation in myelofibrosis: updated recommendations by the EBMT/ELN International Working Group. Lancet Haematol. 2024;11(1):e62‐e74. doi:10.1016/S2352‐3026(23)00305‐8
Gagelmann N, Kroger N. Dose intensity for conditioning in allogeneic hematopoietic cell transplantation: can we recommend “when and for whom” in 2021? Haematologica. 2021;106(7):1794‐1804. doi:10.3324/haematol.2020.268839
Gagelmann N, Salit RB, Schroeder T, et al. High molecular and cytogenetic risk in myelofibrosis does not benefit from higher intensity conditioning before hematopoietic cell transplantation: an international collaborative analysis. Hemasphere. 2022;6(10):e784. doi:10.1097/HS9.0000000000000784
McLornan D, Szydlo R, Koster L, et al. Myeloablative and reduced‐intensity conditioned allogeneic hematopoietic stem cell transplantation in myelofibrosis: a retrospective study by the chronic malignancies working Party of the European Society for Blood and Marrow Transplantation. Biol Blood Marrow Transplant. 2019;25(11):2167‐2171. doi:10.1016/j.bbmt.2019.06.034
Hessling J, Kroger N, Werner M, et al. Dose‐reduced conditioning regimen followed by allogeneic stem cell transplantation in patients with myelofibrosis with myeloid metaplasia. Br J Haematol. 2002;119(3):769‐772. doi:10.1046/j.1365‐2141.2002.03884.x
Kroger N, Holler E, Kobbe G, et al. Allogeneic stem cell transplantation after reduced‐intensity conditioning in patients with myelofibrosis: a prospective, multicenter study of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Blood. 2009;114(26):5264‐5270. doi:10.1182/blood‐2009‐07‐234880
Kroger N, Alchalby H, Klyuchnikov E, et al. JAK2‐V617F‐triggered preemptive and salvage adoptive immunotherapy with donor‐lymphocyte infusion in patients with myelofibrosis after allogeneic stem cell transplantation. Blood. 2009;113(8):1866‐1868. doi:10.1182/blood‐2008‐11‐190975
Kroger N, Zabelina T, Schieder H, et al. Pilot study of reduced‐intensity conditioning followed by allogeneic stem cell transplantation from related and unrelated donors in patients with myelofibrosis. Br J Haematol. 2005;128(5):690‐697. doi:10.1111/j.1365‐2141.2005.05373.x
Claudiani S, Marktel S, Piemontese S, et al. Treosulfan based reduced toxicity conditioning followed by allogeneic stem cell transplantation in patients with myelofibrosis. Hematol Oncol. 2016;34(3):154‐160. doi:10.1002/hon.2183
Atagunduz IK, Klyuchnikov E, Wolschke C, et al. Treosulfan‐based conditioning regimen for second allograft in patients with myelofibrosis. Cancers. 2020;12(11):3098. doi:10.3390/cancers12113098
Gagelmann N, Wolschke C, Badbaran A, et al. Donor lymphocyte infusion and molecular monitoring for relapsed myelofibrosis after hematopoietic cell transplantation. Hemasphere. 2023;7(7):e921. doi:10.1097/HS9.0000000000000921
Passamonti F, Cervantes F, Vannucchi AM, et al. A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG‐MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment). Blood. 2010;115(9):1703‐1708. doi:10.1182/blood‐2009‐09‐245837
Sorror ML, Maris MB, Storb R, et al. Hematopoietic cell transplantation (HCT)‐specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood. 2005;106(8):2912‐2919. doi:10.1182/blood‐2005‐05‐2004
Beelen DW, Trenschel R, Stelljes M, et al. Treosulfan or busulfan plus fludarabine as conditioning treatment before allogeneic haemopoietic stem cell transplantation for older patients with acute myeloid leukaemia or myelodysplastic syndrome (MC‐FludT.14/L): a randomised, non‐inferiority, phase 3 trial. Lancet Haematol. 2020;7(1):e28‐e39. doi:10.1016/S2352‐3026(19)30157‐7
Beelen DW, Stelljes M, Remenyi P, et al. Treosulfan compared with reduced‐intensity busulfan improves allogeneic hematopoietic cell transplantation outcomes of older acute myeloid leukemia and myelodysplastic syndrome patients: final analysis of a prospective randomized trial. Am J Hematol. 2022;97(8):1023‐1034. doi:10.1002/ajh.26620
Robin M, Iacobelli S, Passweg J, Koster L, Potter V, Wilson K. Treosulfan compared to busulfan in allogeneic haematopoietic stem cell transplantation for myelofibrosis: a registry‐based study from the Chronic Malignancies Working Party of the EBMT. Blood. 2023;142(Suppl 1):473.
Murthy GSG, Kim S, Estrada‐Merly N, et al. Association between the choice of the conditioning regimen and outcomes of allogeneic hematopoietic cell transplantation for myelofibrosis. Haematologica. 2023;108(7):1900‐1908. doi:10.3324/haematol.2022.281958
Gagelmann N, Ditschkowski M, Bogdanov R, et al. Comprehensive clinical‐molecular transplant scoring system for myelofibrosis undergoing stem cell transplantation. Blood. 2019;133(20):2233‐2242. doi:10.1182/blood‐2018‐12‐890889
Vannucchi AM, Lasho TL, Guglielmelli P, et al. Mutations and prognosis in primary myelofibrosis. Leukemia. 2013;27(9):1861‐1869. doi:10.1038/leu.2013.119
Malagola M, Polverelli N, Martino M, et al. Busulfan or treosulfan conditioning platform for allogeneic stem cell transplantation in patients aged >60 Y with acute myeloid leukemia/myelodysplastic syndrome: a subanalysis of the GITMO AlloEld study. Transplant Direct. 2023;9(3):e1451. doi:10.1097/TXD.0000000000001451
Malagola M, Polverelli N, Rubini V, et al. GITMO registry study on allogeneic transplantation in patients aged ≥60 years from 2000 to 2017: improvements and criticisms. Transplant Cell Ther. 2022;28(2):96 e1‐96 e11. doi:10.1016/j.jtct.2021.11.006
Polverelli N, Bonneville EF, de Wreede LC, et al. Impact of comorbidities and body mass index on the outcomes of allogeneic hematopoietic cell transplantation in myelofibrosis: a study on behalf of the Chronic Malignancies Working Party of EBMT. Am J Hematol. 2024;99:993‐996. doi:10.1002/ajh.27262
Fein JA, Shimoni A, Labopin M, et al. The impact of individual comorbidities on non‐relapse mortality following allogeneic hematopoietic stem cell transplantation. Leukemia. 2018;32(8):1787‐1794. doi:10.1038/s41375‐018‐0185‐y
Tamari R, Rapaport F, Zhang N, et al. Impact of high‐molecular‐risk mutations on transplantation outcomes in patients with myelofibrosis. Biol Blood Marrow Transplant. 2019;25(6):1142‐1151. doi:10.1016/j.bbmt.2019.01.002
Gagelmann N, Badbaran A, Salit RB, et al. Impact of TP53 on outcome of patients with myelofibrosis undergoing hematopoietic stem cell transplantation. Blood. 2023;141(23):2901‐2911. doi:10.1182/blood.2023019630